Elevated Fecal Calprotectin Without Diarrhea: Diagnostic Approach
In patients with markedly elevated fecal calprotectin (>150 mg/g) but no diarrhea symptoms, proceed directly to endoscopic assessment rather than empiric treatment adjustment. 1
Clinical Context and Rationale
The absence of diarrhea does not exclude significant intestinal inflammation. Patients in "symptomatic remission" (no rectal bleeding, normal stool frequency) can still harbor active endoscopic disease, which is precisely why biomarker monitoring exists. The 2023 AGA guidelines specifically address this scenario.
Recommended Diagnostic Algorithm
Step 1: Confirm the Elevation
- Fecal calprotectin >150 mg/g is the threshold that warrants action 1
- Consider repeat measurement in 3-6 months if you want to avoid immediate endoscopy, but if it remains elevated on repeat testing, endoscopy becomes mandatory 1
Step 2: Proceed to Endoscopy
The guideline explicitly recommends endoscopic assessment over empiric treatment adjustment in asymptomatic patients with elevated biomarkers 1. This is a conditional recommendation with very low certainty of evidence, but it prioritizes patient safety by:
- Avoiding false reassurance from symptom absence alone
- Preventing inappropriate treatment escalation without confirmed inflammation
- Identifying the true extent and severity of disease
Step 3: What the Endoscopy Will Reveal
The elevated calprotectin in an asymptomatic patient suggests one of several possibilities:
For Inflammatory Bowel Disease (if known diagnosis):
- Subclinical endoscopic inflammation (Mayo Endoscopic Score 2-3 in UC) 1
- The specificity of fecal calprotectin >150 mg/g is approximately 69% in asymptomatic patients, meaning ~31% may have false positives 1
- However, sensitivity is 71%, so most patients with elevated levels do have inflammation 1
For Undifferentiated Cases:
- IBD (ulcerative colitis or Crohn's disease) - most likely with calprotectin >150 mg/g 2, 3
- Microscopic colitis (can present without overt diarrhea) 2
- Colorectal neoplasia (though less common, calprotectin can be elevated) 4
- Other inflammatory conditions 5, 6
Critical Nuances
Why Not Treat Empirically?
The guidelines are clear: do not adjust treatment empirically based on elevated biomarkers alone in asymptomatic patients 1. The reasoning:
- You need endoscopic confirmation of inflammation location, extent, and severity
- Treatment decisions (especially starting/switching immunosuppressives) require visual confirmation
- The false positive rate is non-trivial (~31% at >150 mg/g cutoff) 1
The Repeat Testing Option
If you and the patient prefer to avoid immediate endoscopy, repeat fecal calprotectin in 3-6 months is acceptable 1. However:
- This delays diagnosis if true inflammation exists
- If it remains elevated, endoscopy becomes unavoidable
- This approach trades immediate certainty for patient convenience
Disease Extent Matters
Recent 2025 data shows that fecal calprotectin levels correlate with disease extent 7. In patients with pancolitis, levels are significantly higher than in proctitis, even with similar endoscopic activity. This means:
- Very high levels (>1000 mg/g) suggest extensive disease
- Moderate elevations (150-500 mg/g) may indicate limited disease
- But this doesn't change the recommendation: endoscopy is still needed
Common Pitfalls to Avoid
Don't assume symptom absence = no disease: Endoscopic inflammation frequently exists without symptoms, particularly in UC patients who have "adapted" to chronic low-grade inflammation 1
Don't use CRP alone: Normal CRP is less informative in asymptomatic patients and cannot rule out moderate-to-severe inflammation 1
Don't ignore the trend: If this patient previously had normal calprotectin and now it's elevated, this represents a significant change requiring investigation
Don't delay in high-risk patients: Those with prior severe disease, recent medication changes, or risk factors for complications should proceed directly to endoscopy without the repeat testing option
Bottom Line for Clinical Practice
Markedly elevated fecal calprotectin (>150 mg/g) in an asymptomatic patient is an indication for colonoscopy, not reassurance. The absence of diarrhea is irrelevant to the decision-making process. You can offer repeat testing in 3-6 months as an alternative if the patient strongly prefers to avoid endoscopy, but make clear that persistent elevation will necessitate colonoscopy anyway. This approach prevents the morbidity of unrecognized active inflammation while avoiding unnecessary treatment escalation.